2025-10-23 - Analysis Report
Okay, here's a comprehensive analysis of Northrop Grumman Corp (NOC) based on the provided data.

**Report: Northrop Grumman Corp (NOC) Analysis**

**0. Executive Summary**

NOC, a leading global aerospace and defense technology company, is currently trading below its 20-day moving average, but above its 60-day moving average. Its performance has lagged the S&P 500 recently, but analyst ratings remain positive. Recent news suggests potential for long-term growth despite tepid recent performance. A hybrid approach of 100% buy using cash with a small amount of monthly investment is recommended.

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Northrop Grumman Corp is a leading global aerospace and defense technology company.
*   **NOC Cumulative Return:** 54.10%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Relative Divergence:**
    *   Current: -44.8%
    *   Max: 56.8%
    *   Min: -54.9%
    *   Relative Position: 9.0%

**Analysis:** NOC has significantly underperformed the S&P 500 over the period considered, with a current cumulative return lagging by approximately 44.8%. The relative position of 9.0% indicates that NOC's underperformance is near its worst levels relative to the S&P 500 within the historical range.

*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 46.0%   | 65.6%   | 17.0%   | 0.0   | 43.6   |
| 2016-2018  | -2.0%   | 74.3%   | -17.0%  | 0.0   | 34.8   |
| 2017-2019  | 17.0%   | 79.2%   | -5.0%   | 0.9   | 48.9   |
| 2018-2020  | -28.0%  | 79.9%   | -52.0%  | 0.8   | 43.3   |
| 2019-2021  | 43.0%   | 79.9%   | -4.0%   | 0.8   | 55.0   |
| 2020-2022  | 18.0%   | 79.9%   | 19.0%   | 0.3   | 77.5   |
| 2021-2023  | 24.0%   | 82.7%   | 23.0%   | 0.2   | 66.5   |
| 2022-2024  | -15.0%  | 82.7%   | -36.0%  | 0.2   | 66.7   |
| 2023-2025  | 4.0%    | 82.1%   | -60.0%  | 0.1   | 85.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows variable performance across different periods, with significant fluctuations.
*   **MDD:** Maximum Drawdown is consistently high, indicating substantial risk and volatility.
*   **Alpha:** Alpha is often negative, meaning that NOC has underperformed its benchmark, especially in recent years.
*   **Beta:** Beta is generally below 1, suggesting that NOC is less volatile than the market, but this may not be fully reflected in its relative performance.
*   **Cap(B):** Market Capitalization has generally increased over the years.

**2. Recent Stock Price Action**

*   **Current Price:** 599.35
*   **Last Market Data:** Price: 596.48, Previous Close: 599.35, Change: -0.48
*   **5-Day Moving Average:** 600.75
*   **20-Day Moving Average:** 608.49
*   **60-Day Moving Average:** 591.32

**Analysis:** The stock price is currently slightly below its previous close and the 5-day moving average, and below the 20-day moving average, but above the 60-day moving average. This suggests potential short-term downward pressure but medium-term support. The change of -0.48 suggests a small decrease in price.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.05 (Neutral)
*   **PPO:** -0.56 (Bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** -10.2 (Short-term Decrease)
*   **Expected Return (%):** -38.3% (Long-term Underperformance vs. S&P 500)

**Analysis:**

*   The High Investment Recommended MRI is offset by the negative expected return.
*   **MRI:** Indicates a high level of safety for investment.
*   **RSI:** RSI suggests a neutral sentiment.
*   **PPO:** The negative PPO indicates a bearish trend.
*   **Hybrid Signal:** Suggests a safe approach to investment given the MRI.
*   **Recent (20-day) Relative Divergence Change:** Suggests a short-term downward trend relative to the S&P 500.
*   **Expected Return (%):** Indicates that the stock is expected to underperform the S&P 500 significantly over the next two years.

The {'price': 596.48, 'previousClose': 599.35, 'change': -0.48} indicates a slight downward fluctuation in price but not an extreme change that suggests a strong shift.

**4. Recent News & Significant Events**

*   **Headlines:**
    *   Earnings live: Tesla stock falls after earnings miss, IBM sinks
    *   Teledyne's Q3 Earnings & Revenues Beat Estimates, Increase Y/Y
    *   Northrop Remains Poised for Long-Term Growth Despite 'Tepid' Q3, BofA Says
    *   BofA Securities Adjusts Northrop Grumman Price Target to $685 From $650, Maintains Buy Rating
    *   UBS Lifts Price Target on Northrop Grumman to $770 From $769, Keeps Buy Rating
    *   BTIG Research Adjusts Northrop Grumman Price Target to $680 From $630, Maintains Buy Rating

**Analysis:** Despite some recent tepid performance (as highlighted by BofA), analysts remain optimistic about Northrop Grumman's long-term growth prospects. Several firms have raised their price targets, indicating confidence in the company's future value.

**4-2. Analyst Opinions**

*   **Consensus:**
    *   Key: Buy
    *   Mean (1=StrongBuy~5=Sell): 2.10 (~Buy)
    *   Opinions: 18
    *   Target Price (avg/high/low): 655.56 / 770.00 / 533.00
    *   Recent Rating Changes:  (No changes provided, so these are left blank.)

**Analysis:** Analyst consensus is positive, with a general "Buy" recommendation and a mean rating of 2.10. The average target price of $655.56 suggests potential upside from the current price.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출          |
|--------------|-------|---------------|
| 2025-10-21   | 7.69  | 10.42 B$      |
| 2025-07-22   | 8.17  | 10.35 B$      |
| 2025-04-22   | 3.33  | 9.47 B$       |
| 2024-10-24   | 7.02  | 10.00 B$      |
| 2025-10-21   | 7.02  | 10.00 B$      |

**Analysis:**

*   EPS shows variability, with a low point in 2025-04-22, but generally consistent performance.
*   Revenues have been relatively stable.
*   The latest EPS is slightly above the prior year, but the latest revenues are roughly stable.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $10.35B   | 21.35%        |
| 2025-03-31   | $9.47B    | 16.69%        |
| 2024-12-31   | $10.69B   | 18.08%        |
| 2024-09-30   | $10.00B   | 21.07%        |
| 2024-06-30   | $10.22B   | 21.44%        |

**Analysis:**

*   Revenues have been relatively consistent around $10 billion.
*   Profit margins have fluctuated, with the lowest margin in Q1 2025.

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $15.47B   | 7.59%    |
| 2025-03-31   | $14.98B   | 3.21%    |
| 2024-12-31   | $15.29B   | 8.27%    |
| 2024-09-30   | $14.75B   | 6.96%    |
| 2024-06-30   | $14.30B   | 6.57%    |

**Analysis:**

*   Equity has been trending upwards slightly.
*   ROE has been variable.

**7. 종합적인 분석 (Overall Analysis)**

*   **Underperformance:** NOC has underperformed the S&P 500 significantly. The expected return suggests this underperformance may continue.
*   **Analyst Sentiment:** Despite recent underperformance, analysts are generally positive on NOC, with "Buy" ratings and raised price targets.
*   **Financial Health:** Revenues and profit margins have been relatively stable. Equity has been trending upward.
*   **Technicals:** Stock is trading below its 20-day moving average, indicating potential short-term downward pressure.
*   **Risks:** High Maximum Drawdown (MDD) indicates significant risk and volatility.
*   **Recommendation:** The hybrid signal suggests a 100% cash buy for safety. However, the negative expected return suggests caution. Further research is warranted to reconcile analyst optimism with the negative performance outlook. Consider the long-term growth potential and analyst support, but be aware of the potential for continued underperformance.
